Symbolic image FDA Warning Letter: Wholesale Peptide Reprimanded
On June 17, 2026, the FDA sent a warning letter to Wholesale Peptide. The supplier is said to have sold unauthorized drugs under the names Prostamax and Gonadorelin.
In context
Peptide news
Research, regulation, safety and market around peptides - briefly contextualized and sourced.
48 posts ·continuously updated ·independent & ad-free
Symbolic image 
Symbolic image Fermented Peptides: Hype or Next Snack Trend?
Fermented peptides are moving from supplements into snacks - but the science is lagging behind the hype. What's really going on?
Symbolic image INSERM debunks peptide hype: No evidence for miracles
France's health research institute INSERM debunks social media promises about peptides: No serious studies prove muscle building, anti-aging, or better sleep. The authority warns of health risks
Symbolic image Semaglutide for Alcohol Addiction: Phase 3 Study 2026
A randomized phase 3 trial shows that semaglutide significantly reduces heavy drinking days in alcohol use disorder and obesity - a new approach for addiction medicine
Symbolic image FDA approves elamipretide (Forzinity) for Barth syndrome
The FDA granted accelerated approval to elamipretide (Forzinity) as the first therapy for Barth syndrome. The peptide stabilizes mitochondria and improves muscle strength
Symbolic image Protein overload: Fast-food chains discover GLP-1 menus
McDonald's, Chipotle, Subway, and Shake Shack are developing protein-focused menus for GLP-1 users. Chipotle labels items 'GLP-1 friendly'. A billion-dollar shift in the restaurant industry
Symbolic image GLP-1 Boom: Snack Industry Faces $12B in Lost Sales
The peptide boom is hitting the snack industry hard: EY-Parthenon projects up to $12B in lost snack sales over a decade. USDA data shows sales holding steady for now - but pressure is building
Symbolic image Strate Labs closure: Peptide vendor shutdown wave 2026
Strate Labs, a long-running research peptide vendor, will close on July 1, 2026. The shutdown is part of a wave of vendor exits driven by FDA enforcement, ITC lawsuits, payment processor crackdowns, and tightened customs
Symbolic image Swissmedic stops 23 peptide shipments from Poland
On 22 June 2026, Swissmedic, BAZG and SSI inspected 46 peptide shipments in Switzerland and seized 23 - around 80 % came from Poland, often misdeclared